STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS-mutant LUAC. Here, we examine the efficacy of PD-1 inhibitors in these subgroups. Objective response rates to PD-1 blockade differed significantly among KL (7.4%), KP (35.7%), and K-only (28.6%) subgroups (P < 0.001) in the Stand Up To Cancer (SU2C) cohort (174 patients) with KRAS-mutant LUAC and in patients treated with nivolumab in the CheckMate-057 phase III trial (0% vs. 57.1% vs. 18.2%; P = 0.047). In the SU2C cohort, KL LUAC exhibited shorter progression-free (P < 0.001) and overall (P = 0.0015) survival compared with KRASMUT;STK11/LKB1WT LUAC. Among 924 LUACs, STK11/LKB1 alterations were the only marker significantly associated with PD-L1 negativity in TMBIntermediate/High LUAC. The impact of STK11/LKB1 alterations on clinical outcomes with PD-1/PD-L1 inhibitors extended to PD-L1–positive non–small cell lung cancer. In Kras-mutant murine LUAC models, Stk11/Lkb1 loss promoted PD-1/PD-L1 inhibitor resistance, suggesting a causal role. Our results identify STK11/LKB1 alterations as a major driver of primary resistance to PD-1 blockade in KRAS-mutant LUAC. Significance: This work identifies STK11/LKB1 alterations as the most prevalent genomic driver of primary resistance to PD-1 axis inhibitors in KRAS-mutant lung adenocarcinoma. Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets. Cancer Discov; 8(7); 822–35. ©2018 AACR. See related commentary by Etxeberria et al., p. 794. This article is highlighted in the In This Issue feature, p. 781
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In NSCLC, alterations in STK11, KEAP1, and TP53 define biologically distinct molecular subsets with different immune phenotypes and treatment outcomes [75,76].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [76]
In the citing paper
“STK11/LKB1 loss and KEAP1 mutations may contribute to lack of response to different therapies including anti-PD-(L)1 immune checkpoint inhibitors9,10 and KRASG12C inhibitors3,4.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [9]
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [9]
In the citing paper
“However, co-mutations of other genes, especially STK11/LKB1 and KEAP1, were found to mediate resistance to anti-PD-1/PD-L1 therapy in KRAS-mutant NSCLC [156].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [156]
In the citing paper
“KRAS-mutant tumors with TP53 co-mutation often show higher inflammatory signaling and may be more responsive to immune checkpoint blockade.”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [76]
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · cited 2×
“KL KP K-only 54(0) 56(0) 64(0) 25(5) 36(2) 45(4) 10(12) 19(14) 27(18) 4(16) 4(26) 4(34) 2(17) 1(29) 1(37) 1(18) 1(29) 1(37) 1(18) 1(29) 1(37) 0(19) 1(29) 0(38) 0(19) 0(30) 0(38) KL KRASSTK11”
Self-citationNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 3×
“38(0) 38(0) 28(3) 17(8) 2(20) 1(21) 1(21) 1(21) 0(22) 0(22) 61(0) 29(5) 12(14) 5(19) 3(20) 2(21) 2(21) 1(22) 0(23) 18(2) 9(3) 5(5) 3(7) 1(8) 1(8) 0(8) 0(8) 61(0) 14(3) 7(4) 5(4) 3(5) 2(5) 1(5) 0(5) 0(5) 3 6 9 12”
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 2×
“38(0) 38(0) 28(3) 17(8) 2(20) 1(21) 1(21) 1(21) 0(22) 0(22) 61(0) 29(5) 12(14) 5(19) 3(20) 2(21) 2(21) 1(22) 0(23) 18(2) 9(3) 5(5) 3(7) 1(8) 1(8) 0(8) 0(8) 61(0) 14(3) 7(4) 5(4) 3(5) 2(5) 1(5) 0(5) 0(5) 3 6 9 12”
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Months KL KP K-only 54(0) 56(0) 64(0) 11(2) 26(3) 29(0) 5(3) 14(6) 20(3) 4(3) 9(10) 9(8) 2(4) 5(14) 3(13) 2(4) 1(15) 2(14) 1(4) 0(15) 2(14) 1(4) 0(15) 1(14) 0(4) 0(15) 0(15)”
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · cited 4×
“KL KP K-only 54(0) 56(0) 64(0) 25(5) 36(2) 45(4) 10(12) 19(14) 27(18) 4(16) 4(26) 4(34) 2(17) 1(29) 1(37) 1(18) 1(29) 1(37) 1(18) 1(29) 1(37) 0(19) 1(29) 0(38) 0(19) 0(30) 0(38) KL KRASSTK11”
InfluentialPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“11(0) 2(1) 0(3) 0(3) 0(3) 0(3) 0(3) 11(0)”
Self-citationComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Cited by
Items 801–900 of 1,004
Guo, M. Z., Murray, J. C., Ghanem, P., Voong, K. R., Hales, R. K., Ettinger, D. S., Lam, V. K. L., Hann, C. L., Forde, P. M., Brahmer, J. R., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.08.002 · Cited by 12
Dong, H., Li, Y., Tang, Z., Wang, P., Zhong, B., Chu, Q., & Lin, D. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-00991-5 · Cited by 13
He, X., Sun, Y., Lu, J., Naz, F., Ma, S., & Liu, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1117760 · Cited by 16
Zhang, Q., Feng, J., Liu, K., Yang, X., Huang, Y., & Tang, B. (2023) · Immunity Inflammation and Disease · doi:10.1002/iid3.958 · Cited by 14
“Studies have reported that STK11 mutations bear some relation with poor prognosis in patients with cervical cancer, epithelial ovarian cancer, lung cancer, and so forth.20,21 Skoulidis et al.22 demonstrated that STK11 mutations are involved in tumor immunotherapy resistance and immune cell infiltration.”
BackgroundNeoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer
Conroy, M. R., Dennehy, C., & Forde, P. M. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107314 · Cited by 13
Attili, I., Asnaghi, R., Vacirca, D., Adorisio, R., Rappa, A., Ranghiero, A., Lombardi, M., Corvaja, C., Fuorivia, V., Schianca, A. C., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13154476 · Cited by 18
“…of co-occurring alterations in NSCLC involve one actionable gene alteration and one alteration in genes involved in cell survival and proliferation ( TP53 , STK11 , PI3KCA and DNA repair pathways), often defining a negative prognostic role compared with the non-co-mutated counterpart [18,19,23–26].”
BackgroundReyes, A., Muddasani, R., & Massarelli, E. (2024) · Cancers · doi:10.3390/cancers16162919 · Cited by 15
“Both STK11 and KEAP1 predict worse a prognosis and treatment response to ICIs, most notably in combination with KRAS mutations [114,117,118].”
BackgroundCross-omics strategies and personalised options for lung cancer immunotherapy
Yan, Y., Shen, S., Li, J., Su, L., Wang, B., Zhang, J., Lu, J., Luo, H., Han, P., Ke Cheng, X. U., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1471409 · Cited by 14
Self-citationPredictive biomarkers for immune checkpoint inhibitors therapy in lung cancer
Yao, J., Lin, X., Zhang, X., Xie, M., Ma, X., Bao, X., Song, J., Liang, Y., Wang, Q., & Xue, X. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2406063 · Cited by 15
Progress in personalized immunotherapy for patients with brain metastasis
Patel, L. R., Kolundžić, N., & Abedalthagafi, M. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00812-0 · Cited by 17
Ghazali, N., Garassino, M. C., Leighl, N. B., & Bestvina, C. M. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251323985 · Cited by 19
“27,32,44,58 As a specific example, in a combined cohort from four medical centers of 1261 patients, STK11 was associated with significantly worse PFS (HR 2.04, p 0.0001) and OS (HR 2.09, p 0.0001).”
InfluentialChen, C., Chen, X., Zhang, Y., Zhang, Q., & Shi, H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1605085 · Cited by 25
“Conversely, KRAS mutations elevate ROS levels, thereby intensifying DNA damage stress and compelling tumor cells to rely more heavily on residual HR mechanisms for survival (47, 48).”
Nie, W., Gan, L., Wang, X., Gu, K., Qian, F.-F., Hu, M.-J., Zhang, D., Chen, S.-Q., Lü, J., Cao, S.-H., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1865670 · Cited by 13
“suggested that lung adenocarcinoma patients with STK11 and KRAS co-mutation showed significantly shorter PFS and OS with PD-1 axis blockade.(57) Although we could not assess this issue because of insufficient data, none of 5 patients with STK11 and KRAS co-mutation had DCB in our cohort.”
BackgroundLKB1 expression and the prognosis of lung cancer: A meta-analysis
Lin, C., Lin, X., Lin, K., Tan, J., Wei, C., & Liu, T. (2021) · Medicine · doi:10.1097/md.0000000000027841 · Cited by 14
“LKB1 is a tumor suppressor gene encodes a serine threonine kinase with a stability role in the regulation of cellular metabolism and energy homeostasis.([10]) Several studies showed that LKB1 served as a powerful biomarker of tumor functional status could guide clinical trials and patient prognosis assessment.”
BackgroundMorphological and Molecular Characterization of KRAS G12C-Mutated Lung Adenocarcinomas
Pîrlog, R., Piton, N., Lamy, A., Guisier, F., Berindan‐Neagoe, I., Sabourin, J., & Marguet, F. (2022) · Cancers · doi:10.3390/cancers14041030 · Cited by 15
“These two driver mutations have been described as being mutually exclusive by multiple studies analyzing large study samples [7,30,31].”
BackgroundResultSpagnuolo, A., Maione, P., & Gridelli, C. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-948 · Cited by 17
“In a paper by Skoulidis et al. , in KRAS-mutant lung adenocarcinoma, the ORR of immunotherapy was approximately 28.6%, 7.4% and 35.7% in the groups with KRAS mutations alone, KRAS co-mutations with STK11/liver kinase B1 (LKB1) and TP53, respectively (91).”
InfluentialShen, Y., Li, J., Qiang, H., Lei, Y., Chang, Q., Zhong, R., Stella, G. M., Gelsomino, F., Kim, Y. W., Abed, A., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-493 · Cited by 13
Talvitie, E., Liljeroos, L., Vilhonen, H., Orte, K. J., Leivo, I. V. V., Kallajoki, M. A., & Taimen, P. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100832 · Cited by 14
“[7] Skoulidis F, Goldberg ME, Greenawalt DM, et al.”
BackgroundHow to manage KRAS G12C-mutated advanced non-small-cell lung cancer
Ricciuti, B., Mira, A., Andrini, E., Scaparone, P., Michelina, S. V., Pecci, F., Cantini, L., Giglio, A. D., Lamberti, G., Ambrogio, C., et al. (2022) · Drugs in Context · doi:10.7573/dic.2022-7-4 · Cited by 16
Immune Oncology Biomarkers in Lung Cancer: an Overview
Travert, C., Barlési, F., Greillier, L., & Tomasini, P. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00970-3 · Cited by 16
Metabolic Phenotypes, Dependencies, and Adaptation in Lung Cancer
DeNicola, G. M., & Shackelford, D. B. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037838 · Cited by 13
50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic
Naidoo, J., Niroula, A., Uprety, D., Smeltzer, M. P., Geissen, N. M., Osarogiagbon, R. U., Mino-Kenudson, M. A., Yatabe, Y., Higgins, K. A., Desai, A. P., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.06.028 · Cited by 13
Self-citationGoldschmid, H., Kluck, K., Ball, M., Kirchner, M., Allgäuer, M., Winter, H., Herth, F. J. F., Heußel, C. P., Pullamsetti, S. S., Savai, R., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107212 · Cited by 13
Tanaka, I., Koyama, J., Itoigawa, H., Hayai, S., & Morise, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1249237 · Cited by 16
“However, these tumors also exhibit reduced efficacy to immunotherapy, independent of PD-L1 expression and high TMB (18, 28, 29).”
BackgroundInfluentialDou, Y., Zheng, J., Kang, J. Y., Wang, L., Huang, D., Liu, Y., He, C., Lin, C., Lu, C., Wu, D., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110150 · Cited by 13
“5,38 STING has emerged as a key regulator of the innate immune response because of the preferential secretion of tumor promoting cytokines/chemokines and type I IFNs and has also become a target for cancer immunotherapy.”
Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors
Malhotra, J. D., De, S., Nguyen, K., Lee, P. P., & Villaflor, V. M. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03825-z · Cited by 12
“In this cohort of patients, the response rates to PD-(L)1 inhibitors were only 7.4% in the Stand Up To Cancer (SU2C) cohort (174 patients) with KRAS-mutant NSCLC and 0% in patients treated with nivolumab in the CheckMate-057 phase III trial [77].”
BackgroundInfluentialTranscriptional repression by HDAC3 mediates T cell exclusion from Kras mutant lung tumors
McGuire, C. K., Meehan, A. S., Couser, E., Bull, L., Minor, A. C., Kuhlmann-Hogan, A., Kaech, S. M., Shaw, R. J., & Eichner, L. J. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2317694121 · Cited by 15
“Clinically, KRAS, LKB1 mutant lung cancer is resistant to ICIs, and these tumors are characterized by low PD - L1 expression and a paucity of tumor - infiltrating T cells ( 58 ).”
Borzi, C., Galli, G., Ganzinelli, M., Signorelli, D., Vernieri, C., Garassino, M. C., Sozzi, G., & Moro, M. (2020) · Pharmaceuticals · doi:10.3390/ph13110385 · Cited by 15
“LKB1 alterations have been reported to be marker of tumor resistance to immune checkpoint blockade [41,42].”
BackgroundClinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas
Huang, R. S. P., Haberberger, J., Harries, L., Severson, E. A., Duncan, D. L., Ferguson, N. L., Hemmerich, A. C., Edgerly, C. I., Murugesan, K., Xiao, J., et al. (2021) · The Oncologist · doi:10.1002/onco.13753 · Cited by 12
“Importantly, potential resistance biomarkers (STK11 and KEAP1 alterations) for patients treated with immune checkpoint inhibitors (ICPIs) have emerged in several tumor types [6, 7].”
BackgroundSelf-citationZhang, Y., Xiong, L., Xie, F., Zheng, X., Li, Y., Zhu, L., & Sun, J. (2021) · Cancer Medicine · doi:10.1002/cam4.3948 · Cited by 15
“STK11 mutation presented accompanying with TP53 mutation in an EGFR T790M-positive patient, which had been reported as a mediator of the cold tumor immune microenvironment and a major driver of primary resistance to PD-1 axis inhibitors in non-squamous lung adenocarcinoma [21].”
BackgroundSun, L., Li, M., Deng, L., Niu, Y., Tang, Y., Wang, Y., & Guo, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.625593 · Cited by 14
Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors
Pezeshki, P. S., Sharif, P. M., & Rezaei, N. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1929919 · Cited by 14
Corke, L., & Sacher, A. G. (2021) · Current Oncology · doi:10.3390/curroncol29010004 · Cited by 15
“The combination of ACT strategies with other immunotherapeutic strategies (e.g., ICI, cytokines) has significant potential to augment the activity and durability of adoptively transferred immune cell populations.”
BackgroundInfluentialThe Clinical Prediction Value of the Ubiquitination Model Reflecting the Immune Traits in LUAD
Che, Y., Jiang, D., Xu, L., Sun, Y., Wu, Y., Liu, Y., Chang, N., Fan, J., Xi, H., Qiu, D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.846402 · Cited by 12
“TMB facilitates the establishment of personalized immunotherapy approaches within genomic sequencing among LUAD patients, which has been accepted as an independent predicting factor to immune checkpoint inhibitors (40, 41).”
BackgroundSelf-citationYang, Y., Wu, Q., Chen, L., Qian, K., & Xu, X. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-1284 · Cited by 13
“Furthermore, a previous study has reported that people with STK11 or KEAP1 mutations are resistant to immunotherapy (23).”
Tang, X., Ren, X., Huang, T., Miao, Y., Ha, W., Li, Z., Yang, L., & Mi, D. (2023) · Mediators of Inflammation · doi:10.1155/2023/3951940 · Cited by 15
“HCC patients with TP53 mutations have poorer outcomes [39], and the mutation status of TP53 can be used to predict immune response to immunotherapy in a variety of cancer types [40, 41].”
BackgroundVerma, S., Chitikela, S. D., Singh, V., Khurana, S., Pushpam, D., Jain, D., Kumar, S., Gupta, Y., & Malik, P. S. (2023) · Medical Oncology · doi:10.1007/s12032-023-02057-y · Cited by 11
Zuo, B., Wang, L., Li, X., Li, X., Wang, J., Xiong, Y., Lei, J., Zhang, X., Chen, Y., Liu, Q., et al. (2023) · Aging · doi:10.18632/aging.205191 · Cited by 14
Self-citationREG4 is an indicator for KRAS mutant lung adenocarcinoma with TTF-1 low expression
Sun, S., Hu, Z., Huang, S., Ye, X., Wang, J., Chang, J., Wu, X., Wang, Q., Zhang, L., Hu, X., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02988-y · Cited by 12
Self-citationBiomarkers in immunotherapy: literature review and future directions
Pharaon, R. R., Koczywas, M. A., Salgia, S. K., Mohanty, A. R., & Massarelli, E. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.04.15 · Cited by 13
“It was discovered that KRAS-mutated NSCLC tumors that also express STK11 or LKB1 mutations cause primary resistance to anti-PD-L1 antibodies and predict poor outcomes (27).”
BackgroundComprehensive analysis of microenvironment-related genes in lung adenocarcinoma
Tao, Y., Liang, B., & Li, Y. (2020) · Future Oncology · doi:10.2217/fon-2019-0829 · Cited by 13
A TP53-based immune prognostic model for muscle-invasive bladder cancer
Li, H., Lü, H., Cui, W., Huang, Y., & Jin, X. (2020) · Aging · doi:10.18632/aging.202150 · Cited by 15
“TP53 also was reported to be a predictor in immunotherapy of PD-1 in lung carcinomatosis [22].”
BackgroundPanja, S., Rahem, S. M., Chu, C., & Mitrofanova, A. (2020) · Current Genomics · doi:10.2174/1389202921999201224110101 · Cited by 18
“cer (SU2C) East Coast project [2, 9, 65, 66]; (iii) Stand Up To Cancer (SU2C) West Coast project [67-69]; (iv) PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) [70]; (v) Cancer Genome Characterization Initiative (CGCI) [71]; (vi) Therapeutically Applicable Research To Generate Effective Treatments…”
BackgroundSueoka‐Aragane, N., Nakashima, C., Yoshida, H., Matsumoto, N., Iwanaga, K., Ebi, N., Nishiyama, A., Yatera, K., Kuyama, S., Fukuda, M., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3929 · Cited by 14
Hofman, P. M. (2021) · Journal of Molecular Pathology · doi:10.3390/jmp2020015 · Cited by 12
Feng, H., Chen, Y., Xie, Z., Jiang, J., Zhong, Y., Guo, W., Yan, W., Lv, Z., Lu, D., Liang, H., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14137 · Cited by 13
“It is has been reported that only part of KRAS mutant lung cancers could benefit from ICI.”
BackgroundInfluentialEfficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study
Guo, X., Du, H., Li, J., Yang, M., Xiong, A., Zhang, H., & Wu, F. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.85 · Cited by 13
Revealing the contribution of somatic gene mutations to shaping tumor immune microenvironment
Xu, L., Zhu, S., Lan, Y., Yan, M., Jiang, Z., Zhu, J., Liao, G., Ping, Y., Xu, J., Pang, B., et al. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac064 · Cited by 12
Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients
Roosan, M. R., Mambetsariev, I., Pharaon, R. R., Fricke, J., Baroz, A. R., Chao, J., Chen, C., Nasser, M. W., Chirravuri‐Venkata, R., Jain, M., et al. (2021) · Cancers · doi:10.3390/cancers13112776 · Cited by 14
“Concurrent mutations in STK11/KEAP1 act as a major driver in primary resistance to PD1 blockade in KRAS-mutated lung adenocarcinoma [50].”
BackgroundNeoadjuvant immunotherapy for resectable non-small cell lung cancer.
Xie, H., Shi, X., & Wang, G. (2021) · American Journal of Cancer Research · Cited by 16
Galán‐Cobo, A., Stellrecht, C. M., Yilmaz, E., Yang, C., Qian, Y., Qu, X. H., Akhter, I., Ayres, M., Fan, Y.-H., Tong, P., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0448 · Cited by 12
“STK11 (LKB1) is the second most altered tumor suppressor gene in NSCLC, and loss of LKB1 expression leads an aggressive tumor phenotype with worse prognosis and reduced responsiveness to PD1/PD-L1 inhibitors (6, 12, 40).”
BackgroundSelf-citationTønnesen, E. M. T., Stougaard, M., Meldgaard, P., & Lade‐Keller, J. (2022) · Journal of Clinical Pathology · doi:10.1136/jcp-2022-208574 · Cited by 13
Zhang, H., Nabel, C. S., Li, D., O’Connor, R. Í., Crosby, C. R., Chang, S. M., Yuan, H., Stanley, R., Sahu, S., Levin, D. S., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.03.014 · Cited by 14
Self-citationResistance to KRAS inhibition in advanced non-small cell lung cancer
Sreter, K. B., Catarata, M. J., von Laffert, M., & Frille, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1357898 · Cited by 12
Fomin, V., So, W. V., Barbieri, R. A., Hiller-Bittrolff, K., Koletou, E., Tu, T., Gomes, B. D., Cai, J. J., & Charo, J. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009092 · Cited by 12
“32 33 However, our analysis showed that not all mutations in KEAP1 lead to resistance, and while KEAP1 HFM 320 was associated with resistance, LFM were associated with These divergent therapy outcomes to different mutations within the same gene were also found in other genes.”
InfluentialSTK11 mutation status is associated with decreased survival in meningiomas
Gill, C. M., Loewenstern, J., Rutland, J. W., Arib, H., Pain, M., Umphlett, M., Kinoshita, Y., McBride, R. B., Bederson, J. B., Donovan, M. J., et al. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04372-y · Cited by 12
Yuan, D., Wei, Z., Wang, Y., Cheng, F., Zeng, Y., Li, Y., Zhang, S., Li, J., & Tang, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.734873 · Cited by 16
Dey, S., Ashrafi, A., Vidal, C., Jain, N., Kalainayakan, S. P., Ghosh, P., Alemi, P. S., Salamat, N., Konduri, P. C., Kim, J., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0385 · Cited by 11
Zeng, H., Tong, F., Bin, Y., Peng, L., Gao, X., Xia, X., Yi, X., & Dong, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.834142 · Cited by 11
“Mutations in the STK11 gene in NSCLC patients are associated with an inert tumor immune microenvironment with reduced density of infiltrating CD8+ T cells, thus showing a poor response to ICI therapy (15).”
BackgroundClinical M2 Macrophage-Related Genes Can Serve as a Reliable Predictor of Lung Adenocarcinoma
Xu, C., Song, L., Yang, Y., Liu, Y., Pei, D., Liu, J., Guo, J., Liu, N., Li, X., Liu, Y., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.919899 · Cited by 19
Comprehensive analysis of the significance of METTL7A gene in the prognosis of lung adenocarcinoma
Pan, Y.-Q., Xiao, Y., Li, Z., Long, T., Chen, G., Zhu, J., Lv, L., Liu, J., Qi, J.-Q., & Shao, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1071100 · Cited by 14
Yang, J., Shi, W., Yang, Z., Yu, H., Wang, M., Wei, Y., Wen, J., Zheng, W., Zhang, P., Zhao, W., et al. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-171 · Cited by 14
IMPACT: A web server for exploring immunotherapeutic predictive and cancer prognostic biomarkers
Liu, Y., Zhang, Y., Xie, W., Zhao, J., Dong, Y., Xu, C., Wang, Y., Li, M., Wang, G., Xin, Z., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1354 · Cited by 11
Self-citationManagement of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine
Aredo, J. V., & Padda, S. K. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0557-6 · Cited by 12
Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast
Vranić, S., Senarathne, W., Stafford, P., Poorman, K. A., Pockaj, B. A., & Gatalica, Z. (2019) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000808 · Cited by 12
Zhao, D., Mambetsariev, I., Li, H., Chen, C., Fricke, J., Fann, P., Kulkarni, P., Xing, Y., Lee, P. P., Bild, A., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.05.025 · Cited by 11
Cai, X., Chen, Z., Deng, M., Li, Z., Wu, Q., Wei, J., Dai, C., Wang, G., & Luo, C. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-5952 · Cited by 13
“Furthermore, it has been reported STK11 alteration is the primary cause of resistance to PD-1 blockade in KRAS-mutant murine LUAD, suggesting co-occurrence of KRAS mutation and STK11 mutation may be an adverse prognostic factor for ICI therapy (47).”
BackgroundTreatment of Rare Mutations in Patients with Lung Cancer
Taha, T., Khoury, R., Brenner, R. M., Nasrallah, H., Shofaniyeh, I., Yousef, S., & Agbarya, A. (2021) · Biomedicines · doi:10.3390/biomedicines9050534 · Cited by 13
“On the other hand, NTRK-fused NSCLC tumors are known to co-exist with STK11 mutations, which seem to be associated with a poor response to ICIs in KRAS mutant disease [69].”
BackgroundNassar, A. A.-M., Lymona, A. M., Lotfy, M. M., Youssef, A. S. E.-D., Mohanad, M., Manie, T., Youssef, M. M. G., Farahat, I. G., & Zekri, A.-R. (2021) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2021.22.7.2053 · Cited by 11
“immunologically relevant genes can also do, for example; mutations in JAK1, JAK2, B2M, and STK11genes (Skoulidis et al., 2018).”
BackgroundInfluentialDzung, A., Saltari, A., Tiso, N., Lyck, R., Dummer, R., & Levesque, M. P. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.09.035 · Cited by 14
Emerging immunological strategies: recent advances and future directions
Zhao, H., Luo, F., Xue, J., Li, S., & Xu, R. (2021) · Frontiers of Medicine · doi:10.1007/s11684-021-0886-x · Cited by 12
“Although immune checkpoint inhibitors (ICIs) are now widely studied and have shown promising clinical data, many patients receiving ICIs fail to achieve clinical benefits, show varying response rates among different tumor types [1,2], and suffer from risk of immune-related adverse events (irAEs) [3].”
BackgroundZhang, L., Jiang, B.-W., Lan, Z., Yang, C.-M., Yao, Y., Lin, J., & Wei, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.983570 · Cited by 11
Sakamoto, Y., Xu, L., Seki, M., Yokoyama, T., Kasahara, M., Kashima, Y., Ohashi, A., Shimada, Y., Motoi, N., Tsuchihara, K., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/620047 · Cited by 12
Leader, A. M., Grout, J. A., Chang, C., Maier, B. B., Tabachnikova, A., Walker, L. A., Lansky, A., Bérichel, J. L., Malissen, N., Davila, M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.16.207605 · Cited by 13
LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers
Li, C., Syed, M. U., Nimbalkar, A., Shen, Y., Vieira, M. D., Fraser, C., Inde, Z., Qin, X., Ouyang, J., Kreuzer, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58753-y · Cited by 11
“Inactivating mutations or loss of STK11 / LKB1, which de fi ne one of the major genomic sub-groups of KRAS - mutant lung cancers 1,19,62 , are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade 9,63 and poor overall prognosis 64 .”
Tumor immune organoids in immunotherapy resistance and drug screening
Zhang, M., Li, L., Pu, H., Yan, W., Zhang, X., Guo, X., Zhao, Y., Meng, Q., & Yin, M. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101360 · Cited by 12
Immunoradiotherapy for NSCLC: mechanisms, clinical outcomes, and future directions
Weishan, H., Dong-lin, Z., Guangmei, D., Liu, W., Wu, F., & Chen, J. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03337-9 · Cited by 10
Provencio, M., Pérez-Parente, D., Olson, S., Hasan, H., Campos, B., Rodríguez‐Abreu, D., Piqueras, M., Pal, N., Wilkinson, S., Vilas, E., et al. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03362-8 · Cited by 15
“Inactivation of STK11 in lung cancer appears to result in an immunologically cold tumor microenvironment, with reduced T cell infiltration [26–28].”
Kimbrough, E. O., Marin-Acevedo, J. A., Drusbosky, L. M., Mooradian, A., Zhao, Y., Manochakian, R., & Lou, Y. (2024) · Cancers · doi:10.3390/cancers16132366 · Cited by 12
“We found that females were more likely to have alterations with a known targeted therapy ( EGFR , KRAS G12C, ERBB2 ex20), while males were more likely to have mutations in STK11 or TP53 which are associated with poor response to therapy and worse outcomes [61,62].”
BackgroundGeroyska, S., Mejia, I., Chan, A. A., Navarrete, M. S., Pandey, V., Kharpatin, S., Noguti, J., Wang, F., Srole, D. N., Chou, T., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0428 · Cited by 11
“The translocase of the outer mitochondrial membrane 20 (TOM20) complex works along with the translocase of inner mitochondria membrane complexes 22 and 23 (TIM22 and TIM23) to transport proteins from the cytoplasm to the mitochondrial compartments (33).”
BackgroundNovel Spatial Approaches to Dissect the Lung Cancer Immune Microenvironment
Julio, I. C. L., Hernandez, S. D., Wistuba, I. I., & Soto, L. M. S. (2024) · Cancers · doi:10.3390/cancers16244145 · Cited by 10
Self-citationRole of the TME in immune checkpoint blockade resistance of non-small cell lung cancer
Dai, Y., Tian, X., Ye, X., Gong, Y., Xu, L., & Jiao, L. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.166 · Cited by 24
Henick, B. S., Koch, P. D., Gainor, J. F., Awad, M. M., Chiuzan, C. C., Izard, S. M., Georgis, Y., Mallick, S., Garofano, R. F., Wong, C. V., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009301 · Cited by 12
Self-citationRamos-Ramírez, M., Caballé‐Perez, E., Lucio-Lozada, J., Romero-Núñez, E., Castillo-Ruiz, C., Dorantes-Sánchez, L., Flores‐Estrada, D., Recondo, G., Barrios‐Bernal, P., Cabrera-Miranda, L. A., et al. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10245-7 · Cited by 15
“…transcriptional factor by WNT signaling, and promotes an immune “cold” TME, characterized by reduced infiltration of CD3 + CD8 + / PD-1 + T lymphocytes [51], and increased presence of expression of T-cell exhaustion markers, cancer-promoting cytokines [164], and tumor-associated neutrophils [41].”
Shu, C., Li, J., Rui, J., Fan, D., Niu, Q., Bai, R., Cicka, D., Doyle, S. P., Wahafu, A., Zheng, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57297-5 · Cited by 13
“For example, LKB1-mut LUAD cells have altered expres-sionofproin fl ammatorycytokinesandimmunecheckpointmolecules, reprogrammed immune in fi ltration, and remodeled extracellular matrix 9,29,32 – 36 .”
InfluentialA SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy
Marron, T. U., Luke, J. J., Hoffner, B., Perlmutter, J., Szczepanek, C. M., Anagnostou, V., Silk, A. W., Romero, P. J., Garrett-Mayer, E. S., & Emens, L. A. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010760 · Cited by 12
Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?
Fu, S., Ma, J., Cai, C., Tan, J., Deng, X., Shen, H., Zeng, S., Chen, Y., & Han, Y. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03444-1 · Cited by 14
Minor, A. C., Couser, E., & Eichner, L. J. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.06.008 · Cited by 16
Jin, Z., Zhang, Q., Pan, Y., Chen, H., Zhou, K., Cai, H., & Huang, P. (2025) · Current Oncology · doi:10.3390/curroncol32080456 · Cited by 15
“These co-mutations shape a distinct metabolic–immune phenotype, significantly enhancing ferroptosis tolerance in this particular tumor subtype [76].”
Bhalla, S., Doroshow, D. B., & Hirsch, F. R. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000483 · Cited by 11
Zhou, Y.-X., Chen, P., Sun, Y., Zhang, B., & Qiu, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.698732 · Cited by 10
Negrao, M. V., Papadimitrakopoulou, V. A., Price, A. C., Tam, A. L., Furqan, M., Laroia, S., Massarelli, E., Pacheco, J. M., Heymach, J. V., Tsao, A. S., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100423 · Cited by 13
Self-citationWlosik, J., Fattori, S., Rochigneux, P., Gonçalvès, A., Olive, D., & Chrétien, A.-S. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00973-1 · Cited by 17
Castelo-Branco, L., Morgan, G., Prelaj, A., Scheffler, M., Canhão, H. M., van Meerbeeck, J. P., & Awada, A. H. (2023) · ESMO Open · doi:10.1016/j.esmoop.2022.100764 · Cited by 11
Lee, S., Wang, F., Grefe, M., Trujillo‐Ocampo, A., Ruiz‐Vasquez, W., Takahashi, K., Abbas, H. A., Borges, P., Antunes, D. A., Alatrash, G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2601 · Cited by 10
Chmielewska, I., Krawczyk, P. A., Grenda, A., Wójcik-Superczyńska, M., Krzyżanowska, N., Gil, M., & Milanowski, J. (2023) · Cancers · doi:10.3390/cancers15143732 · Cited by 13
“These data come from two clinical trials: SU2C and CheckMate 057 [62].”
MethodBiomarkers of immunotherapy for non-small cell lung cancer
Shirasawa, M., Yoshida, T., & Ohe, Y. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad134 · Cited by 11
Hirsch, D. D., Gaiser, T., Merx, K., Weingärtner, S., Förster, M., Hendricks, A., Woenckhaus, M., Schubert, T., Hofheinz, R., & Gencer, D. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03335-2 · Cited by 10
Immunotherapy in oncogene addicted non-small cell lung cancer
McLean, L. S., Leal, J. L., Solomon, B., & John, T. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-772 · Cited by 11
“…all treated with ICIs, patients with KRAS - STK11 co-mutations demonstrated a significantly lower ORR, PFS and OS than patients with KRAS - TP53 tumours (77); furthermore, STK11 was associated with resistance to PD-1 blockade in PD-L1 positive NSCLC, regardless of KRAS mutational status (77).”
Genetic heterogeneity and predictive biomarker for pulmonary sarcomatoid carcinomas
Qin, J., Chen, B., Li, C., Yan, J., & Lu, H. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.11.004 · Cited by 11
Metadata
- Authors
- Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., Ali, S. M., Elvin, J. A., Singal, G., Ross, J. S., Fabrizio, D., Szabo, P. M., Chang, H., Sasson, A., Srinivasan, S., Kirov, S., Szustakowski, J., Vitazka, P., Edwards, R., Bufill, J. A., Sharma, N., Ou, S.-H. I., Peled, N., Spigel, D. R., Rizvi, H., Aguilar, E. J., Carter, B. W., Erasmus, J., Halpenny, D. F., Plodkowski, A. J., Long, N. M., Nishino, M., Denning, W. L., Galan-Cobo, A., Hamdi, H., Hirz, T., Tong, P., Wang, J., Rodriguez-Canales, J., Villalobos, P. A., Parra, E. R., Kalhor, N., Sholl, L. M., Sauter, J. L., Jungbluth, A. A., Mino-Kenudson, M., Azimi, R., Elamin, Y. Y., Zhang, J., Leonardi, G. C., Jiang, F., Wong, K.-K., Lee, J. J., Papadimitrakopoulou, V. A., Wistuba, I. I., Miller, V. A., Frampton, G. M., Wolchok, J. D., Shaw, A. T., Jänne, P. A., Stephens, P. J., Rudin, C. M., Geese, W. J., Albacker, L. A., & Heymach, J. V.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Foundation Medicine (United States) (US)
- Bristol-Myers Squibb (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Massachusetts General Hospital (US)
- 3Bristol-Myers Squibb Co., Princeton, New Jersey.
- 7Michiana Hematology Oncology, Mishawaka, Indiana.
- 8Novartis Institute of Biomedical Research, East Hanover, New Jersey.
- University of California, Irvine (US)
- Tel Aviv University (IL)
- Sarah Cannon (US)
- 5Lowe Center for Thoracic Oncology and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Brigham and Women's Hospital (US)
- 1Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 17Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- NYU Langone Health (US)
- Corresponding author
- Albacker, Lee A.
- Heymach, John V.
- ORCID
- Skoulidis, Ferdinandos
- Goldberg, Michael E.
- Greenawalt, Danielle M.
- Hellmann, Matthew D.
- Awad, Mark M.
- Gainor, Justin F.
- Schrock, Alexa B.
- Hartmaier, Ryan J.
- Trabucco, Sally E.
- Gay, Laurie
- Ali, Siraj M.
- Elvin, Julia A.
- Ross, Jeffrey S.
- Fabrizio, David
- Sasson, Ariella
- Srinivasan, Sujaya
- Kirov, Stefan
- Szustakowski, Joseph
- Edwards, Robin
- Sharma, Neelesh
- Ou, Sai-Hong I.
- Peled, Nir
- Spigel, David R.
- Rizvi, Hira
- Carter, Brett W.
- Plodkowski, Andrew J.
- Nishino, Mizuki
- Denning, Warren L.
- Hirz, Taghreed
- Tong, Pan
- Wang, Jing
- Parra, Edwin R.
- Kalhor, Neda
- Sholl, Lynette M.
- Sauter, Jennifer L.
- Jungbluth, Achim A.
- Mino-Kenudson, Mari
- Elamin, Yasir Y.
- Zhang, Jianjun
- Leonardi, Giulia C.
- Jiang, Fei
- Wong, Kwok-Kin
- Papadimitrakopoulou, Vassiliki A.
- Wistuba, Ignacio I.
- Miller, Vincent A.
- Frampton, Garrett M.
- Wolchok, Jedd D.
- Shaw, Alice T.
- Rudin, Charles M.
- Geese, William J.
- Albacker, Lee A.
- Heymach, John V.
- Venue
- Cancer Discovery
- Published
- 2018-07-01
- Volume
- 8
- Issue
- 7
- Pages
- 822-835
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6030433
- OpenAlex
- W2804812017
- Cited by
- 1,641
- References
- 56
- Citations by year
- 2026: 182 · 2025: 191 · 2024: 196 · 2023: 211 · 2022: 223 · 2021: 264 · 2020: 239 · 2019: 108 · 2018: 26
- FWCI
- 59.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- American Association for Cancer Research (AACR) (SU2C-AACR-DT17-15)
- HHS | NIH | National Cancer Institute (NCI) (P30 CA016672, P30 CA008748, P50 CA070907, 1R01 CA205150, 1R01 CA203636)
- Sabin Family Foundation (Sabin Family Foundation Fellowship)
- Khalifa Bin Zayed Al Nahyan Foundation (Khalifa Bin Zayed Al Nahyan Foundation Scholar Award)
- Jane Ford-Petrin Fund (Jane Ford-Petrin Fund)
- Cancer Prevention and Research Institute of Texas (CPRIT) (RP160652)
- V Foundation for Cancer Research (V Foundation) (V Foundation Translational Award)
- The University of Texas MD Anderson Lung Cancer Moonshots Program
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- KRAS-mutant lung adenocarcinoma, anti-PD-1 resistance, PD-L1 expression, tumor mutational burden, nivolumab, immune checkpoint inhibitors, TP53 mutation, non-small cell lung cancer, immunotherapy biomarkers, combination immunotherapy, progression-free survival
- MeSH terms
- Antineoplastic Agents, Immunological, Adenocarcinoma of Lung, Nivolumab, Progression-Free Survival, AMP-Activated Protein Kinase Kinases, Adult, Aged, Aged, 80 and over, Animals, Disease Models, Animal, Humans, Immunotherapy, Lung Neoplasms, Male, Middle Aged, Mutation, Prognosis, Proto-Oncogene Proteins p21(ras), Protein Serine-Threonine Kinases, Drug Resistance, Neoplasm, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.